Lupin FY26 Revenue Surges 23.9% to ₹2,74,875 Crore, Q4 Profit Jumps 87.7%
Lupin Limited reported FY2026 results with sales of ₹2,74,875 crore, up 23.9%. Q4 FY2026 PAT grew 87.7% to ₹14,687 crore. U.S. sales surged 46.0% to ₹1,16,783 crore. The company recommended a 900% dividend.
The announcement details robust financial performance with significant growth across key metrics and geographies. The recommended dividend of 900% is a material event for shareholders, indicating strong financial health and confidence. The strong performance in the U.S. market is also a significant factor.
The company reported strong year-on-year growth in sales, EBITDA, and profit after tax for both the full fiscal year and the fourth quarter. Significant growth in key markets like the U.S. and a substantial dividend recommendation further contribute to the positive sentiment.
Lupin Limited announced its audited financial results for the fiscal year and fourth quarter ended March 31, 2026. The Board of Directors recommended a dividend of 900%.
For the full fiscal year 2026, Lupin reported sales of ₹2,74,875 crore, a significant increase of 23.9% compared to ₹2,21,921 crore in FY2025. EBITDA grew by 68.6% to ₹92,405 crore, and Profit After Tax (PAT) surged by 62.0% to ₹53,555 crore.
In the fourth quarter of FY2026, sales reached ₹73,919 crore, up 32.9% year-on-year from ₹55,622 crore in Q4 FY2025. EBITDA saw a substantial increase of 90.6% to ₹26,263 crore, and PAT grew by an impressive 87.7% to ₹14,687 crore.
The U.S. market was a key driver, with sales for FY2026 increasing by 46.0% to ₹1,16,783 crore (USD 1,318 million), accounting for 42% of global sales. Q4 FY2026 U.S. sales grew by 56.9% to ₹33,987 crore (USD 371 million), representing 46% of global sales. The company received 3 ANDA approvals and launched 3 products in the U.S. during the quarter, expanding its generic product portfolio to 151.
Sales in India for FY2026 increased by 7.1% to ₹81,140 crore, contributing 30% to global sales. Q4 FY2026 India sales rose by 11.5% to ₹19,082 crore.
Emerging Markets also showed strong growth, with FY2026 sales up 35.2% to ₹34,828 crore and Q4 FY2026 sales up 49.2% to ₹9,906 crore.
Global API sales for FY2026 were ₹9,685 crore, a decrease of 17.7%. Investment in R&D for FY2026 was ₹20,631 crore (7.5% of sales).
Mr. Nilesh Gupta, Managing Director, Lupin Limited, stated, "Our fourth quarter and full-year results underscore the strength and resilience of our business across key geographies, with the U.S. and India delivering strong sales growth and margin expansion. Building on this momentum, we are well-positioned to accelerate performance through strategic investments in technology, disciplined execution, and operational efficiencies, driving sustainable and profitable growth."
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.